New frontiers in the medical management of gastrointestinal stromal tumours.

Article Details

Citation

Copy to clipboard

Mazzocca A, Napolitano A, Silletta M, Spalato Ceruso M, Santini D, Tonini G, Vincenzi B

New frontiers in the medical management of gastrointestinal stromal tumours.

Ther Adv Med Oncol. 2019 May 17;11:1758835919841946. doi: 10.1177/1758835919841946. eCollection 2019.

PubMed ID

31205499 [ View in PubMed

]

Abstract

The tyrosine kinase inhibitor (TKI) imatinib has radically changed the natural history of KIT-driven gastrointestinal stromal tumours (GISTs). Approved second-line and third-line medical therapies are represented by the TKIs sunitinib and regorafenib, respectively. While imatinib remains the cardinal drug for patients with GISTs, novel therapies are being developed and clinically tested to overcome the mechanisms of resistance after treatments with the approved TKI, or to treat subsets of GISTs driven by rarer molecular events. Here, we review the therapy of GISTs, with a particular focus on the newest drugs in advanced phases of clinical testing that might soon change the current therapeutic algorithm.

DrugBank Data that Cites this Article

Drugs

Ripretinib

Avapritinib

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Ripretinib	Platelet-derived growth factor receptor alpha	Protein	Humans	Yes	Inhibitor	Details